Clinical Trials A continuación, se enumeran los ensayos clínicos actuales.525 estudios en Cancer (solo estudios abiertos). Filtra esta lista de estudios por sede, estado, etc. Oligomets pancreas SBRT Jacksonville, Fla. The primary endpoint for this study will compare PFS between SBRT + standard chemotherapy vs. standard chemotherapy alone in patients with oligometastatic pancreatic cancer. PFS is defined as the time from randomization to the first of either disease progression or death from any cause, where disease progression will be determined based on RECIST 1.1 criteria and will be documented at each enrolling site with no central review planned. A Study to Determine the Best Individualized Cancer Therapy Using Circulating Tumor DNA (ctDNA) in Patients with GI, CNS, and Thoracic Cancers. Jacksonville, Fla. This study proposes to develop and maintain a biorepository of blood samples collected from patients receiving definitive chemoradiotherapy for locally advanced rectal cancer, locally advanced pancreatic cancer, non-small cell lung cancer, or cervical cancer. The ultimate goal of this biorepository will be to provide the resource to initiate an exploration of ctDNA as a potential liquid biopsy for GI and Thoracic malignancy detection and surveillance. A Study to Compare Optimal MRI Timing for Pre-surgical Planning to LINAC-based Therapy Rochester, Minn. The purpose of this research is to compare two different standard-of-care pre-surgical imaging methods. Cutaneous Lymphoma Database Scottsdale/Phoenix, Ariz. The purpose of this study is to create a long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions. Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men Jacksonville, Fla. The objective of this pilot stdy is to plan, develop and establish the acceptance and usability of a Point of Prostate Cancer Diagnosis (PPCD) iCCaRE Virtual Robot Assistant (ViRA). The specific aims of this study are to plan and develop a PPCD iCCaRE ViRA model that will provide social determinants of health (SDOH) navigation services, psycho-oncology support and emotional support using qualitative formative research, and to establish the acceptance and usability of the iCCaRE ViRA at a urology clinic among 50 Black men (BM). Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma Jacksonville, Fla. The purpose of this study is to evaluate abemaciclib versus placebo to treat Advanced Dedifferentiated Liposarcoma. Patients with progression of disease will cross over to open label abemaciclib. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab Rochester, Minn. The primary objective of this study is to determine the safety profile of SX-682 alone and in combination with pembrolizumab in subjects with metastatic melanoma, including the maximum dose that can be administered until adverse effects prevent further dose increases (i.e., the MTD or recommended phase 2 dose), and the dose-limiting toxicity (DLT). The secondary objectives are to evaluate the efficacy of SX-682 in combination with pembrolizumab on the basis of the objective response rate, the duration of response, and the rate of progression, and to characterize the single-dose and multidose pharmacokinetic (PK) profile of SX-682. A Study to Evaluate Performance of Coagulation Laboratory Testing in Children and Young Adults Rochester, Minn. The primary purpose of this study is to generate pediatric-specific reference ranges that take into account patient sex, age, corrected gestational age, ethnicity, etc., and laboratory variables for various coagulation studies. Dose-Escalation Study of cevostamab (BFCR4350A) in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) Scottsdale/Phoenix, Ariz. This is a phase I, multicenter, open-label, dose-escalation study of cevostamab (BFCR4350A) administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM). A Study to Evaluate Chemotherapy-Induced Nausea in Breast Cancer Patients Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of the study is to alleviate the occurrence of chemotherapy-induced nausea (CIN) and to improve chemotherapy treatment outcomes. Recent research has shown that changes in the functions performed by the gut microbiome can cause the occurrence of chemotherapy-induced symptoms that include chemotherapy-induced nausea. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 11 Ir a página 22 Ir a página 33 Ir a página 44 Ir a página 55 SiguientePróxima página Profesionales médicos Cancer clinical-trials